-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the State Medical Products Administration approved the marketing
of the Class 1 innovative drug Torudiven Lafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) declared by Shandong Luye Pharmaceutical Co.
, Ltd.
The drug is an innovative drug independently developed by China with independent intellectual property rights, which is suitable for the treatment
of depression.
of the Class 1 innovative drug Torudiven Lafaxine hydrochloride sustained-release tablets (trade name: Ruoxinlin) declared by Shandong Luye Pharmaceutical Co.
, Ltd.
The drug is an innovative drug independently developed by China with independent intellectual property rights, which is suitable for the treatment
of depression.
The antidepressant effect of torludivenlafaxine hydrochloride may be related to
the enhancement of 5-HT, NE effects of the central nervous system by inhibiting the reuptake of serotonin (5-HT), norepinephrine (NE).
The launch of the drug provides more treatment options
for patients with depression.
the enhancement of 5-HT, NE effects of the central nervous system by inhibiting the reuptake of serotonin (5-HT), norepinephrine (NE).
The launch of the drug provides more treatment options
for patients with depression.
